• Call Our Support
    +91-9958406102

  • Our Working Hours
    Mon - Sat: 9:30 am - 6 pm

Glenmark Pharmaceuticals gets USFDA tentative nod for Calcipotriene and Betamethasone Dipropionate Foam



Glenmark Prescribed drugs Inc., USA (Glenmark) has been granted tentative approval by america Meals & Drug Administration (U.S. FDA) for Calcipotriene and Betamethasone Dipropionate Foam, 0.005%|0.064%, the generic model of Enstilar Foam, 0.005%|0.064%, of Leo Pharma AS.

Based on IQVIATM gross sales knowledge for the 12 month interval ending March 2022, the Enstilar Foam, 0.005%|0.064% market achieved annual gross sales of roughly $115.2 million.

Glenmark’s present portfolio consists of 174 merchandise licensed for distribution within the U.S. market and 48 ANDA’s pending approval with the U.S. FDA. Along with these inside filings, Glenmark continues to establish and discover exterior improvement partnerships to complement and speed up the expansion of its current pipeline and portfolio.

At home entrance, on the BSE Glenmark Pharmaceuticals was buying and selling at Rs408 apiece down by Rs2.75 or 0.67%, at round 10:16 AM.



Source link

Get Access To Free Mt4 Indicators & Much More